Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development
ROCKVILLE, Md.–(BUSINESS WIRE)–#allergies–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D.,…